Insight into the treatment of Metastatic Pancreatic/intestine/ovarian Cancer: Rhamnetin suppresses the expression of PDGF Receptor β via up regulation of its target gene, 6/May/2014, 9.44 am

Mechanistic insights into enhanced generation of iPSCs: The arthritis drug Withaferin A (WFA) increases the expression of reprogramming protein Sox-2 via up regulation of its target gene, 6/May/2014, 9.35 am
May 6, 2014
Tumorigenesis: Neurotensin suppresses the expression of tumor suppressor Big-h3 via up regulation of its target gene, 6/May/2014, 10.08 am
May 6, 2014
Show all

A study from Watson School of Biological Sciences shows that Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling. This study was published in the April 10, 2014 Cell by Prof. Dr Scott Lowe, Watson School of Biological Sciences, CSHL, New YorkProf. Dr Carol Prives, Department of Biological Sciences, Columbia University, New York; and others.

On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that:  Insight into the treatment of Metastatic Pancreatic/intestine/ovarian Cancer: Rhamnetin suppresses the expression of  PDGF Receptor β via up regulation of its target gene. Given that tumor suppressor p53 is mutated in about 50% of different human cancers, this study suggests, for the first time, a therapeutic strategy as to how mutant p53 expressing human cancers can be cured.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Insight into the treatment of Metastatic Pancreatic/intestine/ovarian Cancer:  Rhamnetin suppresses the expression of  PDGF Receptor β via up regulation of its target gene, 6/May/2014, 9.44 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Comments are closed.